文献速递流行病学与生物统计临床试验与 GCP

贝叶斯篮子试验设计中的可交换性监测

Bayesian basket trial design with exchangeability monitoring.
PubMed 文献 · Stat Med · 2018-07-08

该文提出一种用于序贯篮子试验设计的贝叶斯监测方法,通过分层模型在可能不可交换的亚型间共享信息。该方法基于一项在六个原发疾病部位与组织学中评估维莫非尼对BRAFV600突变非黑色素瘤疗效的篮子试验,进行了分析及置换与模拟研究。

要点

  • 篮子试验按药物靶点而非组织学分型定义患者亚组。
  • 新方法采用贝叶斯监测规则进行序贯设计。
  • 分层模型在可能不可交换的亚型间共享信息。

核心结论

  • 提出了一种基于贝叶斯监测规则的序贯篮子试验设计新方法。

研究设计与样本

  • 方法学研究,基于一项评估维莫非尼在BRAFV600突变非黑色素瘤六个原发疾病部位与组织学中疗效的篮子试验,进行数据分析、置换检验与模拟研究。

主要发现

  • interim分析基于一种新的分层建模策略,在离散且可能不可交换的亚型集合间共享信息。

局限性

  • 早期篮子试验设计依赖按篮子分别分析,在入组不均衡时把握度有限,且未能向临床界传达所研究临床亚型间疗效一致性的证据度量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Precision medicine endeavors to conform therapeutic interventions to the individuals being treated. Implicit to the concept of precision medicine is heterogeneity of treatment benefit among patients and patient subpopulations. Thus, precision medicine challenges conventional paradigms of clinical translational which have relied on estimates of population-averaged effects to guide clinical practice. Basket trials comprise a class of experimental designs used to study solid malignancies that are devised to evaluate the effectiveness of a therapeutic strategy among patients defined by the presence of a particular drug target (often a genetic mutation) rather than a particular tumor histology. Acknowledging the potential for differential effectiveness on the basis of traditional criteria for cancer subtyping, evaluations of treatment effectiveness are conducted with respect to the "baskets" which collectively represent a partition of the targeted patient population consisting of discrete subtypes. Yet, designs of early basket trials have been criticized for their reliance on basketwise analysis strategies that suffered from limited power in the presence of imbalanced enrollment as well as failed to convey to the clinical community evidentiary measures for consistent effectiveness among the studied clinical subtypes. This article presents novel methodology for sequential basket trial design formulated with Bayesian monitoring rules. Interim analyses are based a novel hierarchical modeling strategy for sharing information among a collection of discrete potentially nonexchangeable subtypes. The methodology is demonstrated by analysis as well as permutation and simulation studies based on a recent basket trial designed to estimate the effectiveness of vemurafenib in BRAFV600 mutant non-melanoma among six primary disease sites and histologies.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Hobbs BP, Landin R. Bayesian basket trial design with exchangeability monitoring. Stat Med. 2018. PMID: 29984488. doi:10.1002/sim.7893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。